Abstract: A composite sintered body including: a metal oxide as a main phase; silicon carbide as a sub-phase; and silicate of a metal element that is included in the metal oxide, in which the average aggregation diameter of the silicate in the field of view of 600 ?m2 at a magnification of 1000 times is 5 ?m or lower.

Abstract: An on-vehicle hands-free apparatus according to the present disclosure enables a hands-free call by being connected to a mobile phone in a wireless or wired manner. The on-vehicle hands-free apparatus includes a memory, and a hardware processor coupled to the memory. The hardware processor is configured to: cause the mobile phone to execute an outgoing/incoming call using a phone function of the mobile phone based on outgoing/incoming call history data or phone book data stored in the mobile phone, the outgoing/incoming call history data including a phone number transmitted and received by the mobile phone; and acquire the outgoing/incoming call history data including a phone number of a counterpart of a call from the mobile phone when the call is terminated on the mobile phone.

Abstract: An on-vehicle hands-free apparatus according to the present disclosure enables a hands-free call by being connected to a mobile phone in a wireless or wired manner. The on-vehicle hands-free apparatus includes a memory, and a hardware processor coupled to the memory. The hardware processor is configured to: cause the mobile phone to execute an outgoing/incoming call using a phone function of the mobile phone based on outgoing/incoming call history data or phone book data stored in the mobile phone, the outgoing/incoming call history data including a phone number transmitted and received by the mobile phone; and acquire the outgoing/incoming call history data including a phone number of a counterpart of a call from the mobile phone when the call is terminated on the mobile phone.

Abstract: Transformed cells designed to express a recombinant human SMBP at an elevated level to the extent that its ligand-binding activity can be measured, and cellular membrane fractions thereof; recombinant human SMBPs isolated from the transformed cells or the cellular membrane fractions thereof; a screening system for human SMBP agonists/antagonists characterized by utilizing the transformed cells, the cellular membrane fractions thereof or the isolated recombinant human SMBPs; and human SMBP agonists or antagonists obtainable by the screening system, are provided by deleting the polythymidine sequence from the base sequence of the 3?-untranslated region.

Abstract: Transformed cells designed to express a recombinant human SMBP at an elevated level to the extent that its ligand-binding activity can be measured, and cellular membrane fractions thereof; recombinant human SMBPs isolated from the transformed cells or the cellular membrane fractions thereof; a screening system for human SMBP agonists/antagonists characterized by utilizing the transformed cells, the cellular membrane fractions thereof or the isolated recombinant human SMBPs; and human SMBP agonists or antagonists obtainable by the screening system, are provided by deleting the polythymidine sequence from the base sequence of the 3′-untranslated region.

Abstract: Transformed cells designed to express a recombinant human SMBP at an elevated level to the extent that its ligand-binding activity can be measured, and cellular membrane fractions thereof; recombinant human SMBPs isolated from the transformed cells or the cellular membrane fractions thereof; a screening system for human SMBP agonists/antagonists characterized by utilizing the transformed cells, the cellular membrane fractions thereof or the isolated recombinant human SMBPs; and human SMBP agonists or antagonists obtainable by the screening system, are provided by deleting the polythymidine sequence from the base sequence of the 3′-untranslated region.